Free Trial
TSE:MRV

Nuvo Pharmaceuticals (MRV) Stock Price, News & Analysis

About Nuvo Pharmaceuticals Stock (TSE:MRV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
C$1.35
C$1.35
52-Week Range
N/A
Volume
6,732 shs
Average Volume
27,569 shs
Market Capitalization
C$15.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Receive MRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRV Stock News Headlines

Holdco Nuvo Group Dg Ltd Share Chat
Holdco Nuvo Group D.G Ltd (NUVO)
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
Taro Pharmaceutical Industries Ltd.
Ionis Pharmaceuticals Inc IONS
Nuvoco Vistas Corporation Ltd (NUVO)
LIPO Lipella Pharmaceuticals Inc.
See More Headlines

MRV Stock Analysis - Frequently Asked Questions

Shares of MRV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvo Pharmaceuticals investors own include Biora Therapeutics (BIOR), ACM Research (ACMR), Achieve Life Sciences (ACHV), Achilles Therapeutics (ACHL), Adicet Bio (ACET), Acer Therapeutics (ACER) and Air Canada (AC).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$15.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$72.42 million
Book Value
C$0.75 per share

Miscellaneous

Free Float
N/A
Market Cap
C$15.38 million
Optionable
Not Optionable
Beta
0.78
10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (TSE:MRV) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners